Danoprevir (Synonyms: ITMN-191; R7227; RO5190591; RG7227)

Name: Danoprevir
Brand: MedChemExpress
SKU: HY-10238
Rating: 5.0 (18 reviews)

Cat. No.: HY-10238 Purity: 99.69%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM). Danoprevir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 0.05 μM.

For research use only. We do not sell to patients.

Danoprevir Chemical Structure

CAS No. : 850876-88-9

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 274	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 274	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 170	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 300	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 555	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 850	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 1300	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 18 publication(s) in Google Scholar

Other Forms of Danoprevir:

Danoprevir sodium Get quote

17 Publications Citing Use of MCE Danoprevir

: Danoprevir purchased from MedChemExpress. Usage Cited in: Virology. 2014 May;456-457:300-9. [Abstract]; Jurkat cells are transfected with plasmids expressing (A) HCV NS3/4A or (B) HPgV NS3/4AB-HA. Telaprevir, Boceprevir, and Danoprevir are added at concentrations of 100 µM, 16.6 µM, 2.7 µM, or 0 µM in 0.1% DMSO. Lysates are harvested after 24 h and resolved by immunoblots probed with anti-HCV NS3 (A) or anti-HA (B). The position of HCV NS3/4A (~75kDa), HCV NS3 (~73kDa), NS3/4AB-HA, and NS4B-HA (~30kDa) are indicated. Molecular markers are on the right.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM)^[1]^[2]. Danoprevir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 0.05 μM^[3].

IC₅₀ & Target

IC50: 0.29 nM (NS3/4A protease), 0.2-3.5 nM (HCV genotypes 1a, 1b, 2b, 3a, 4, 5, 6)^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	EC₅₀	< 0.25 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA Antiviral activity against Hepatitis C virus harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA	[PMID: 23672640]
Huh-7	EC₅₀	0.011 μM Compound: 5	Antiviral activity against HCV infected in human HuH7 cells by cell based replicon assay Antiviral activity against HCV infected in human HuH7 cells by cell based replicon assay	[PMID: 27160057]
Huh-7	IC₅₀	0.24 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay	[PMID: 23672640]
Huh-7	EC₅₀	0.25 nM Compound: ITMN-191	Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	EC₅₀	0.5 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA Antiviral activity against Hepatitis C virus harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA	[PMID: 23672640]
Huh-7	EC₅₀	0.6 nM Compound: ITMN-191	Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	EC₅₀	0.62 nM Compound: ITMN-191	Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	EC₅₀	1 nM Compound: ITMN191	Antiviral activity against HCV 1a infected in human Huh-7 cells after 48hrs by luciferase assay Antiviral activity against HCV 1a infected in human Huh-7 cells after 48hrs by luciferase assay	[PMID: 21067923]
Huh-7	EC₅₀	1.1 nM Compound: ITMN191	Antiviral activity against HCV 1b infected in human Huh-7 cells after 48hrs by luciferase assay Antiviral activity against HCV 1b infected in human Huh-7 cells after 48hrs by luciferase assay	[PMID: 21067923]
Huh-7	EC₅₀	1.6 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis	[PMID: 23672640]
Huh-7	EC₅₀	2.1 nM Compound: RG-7227, ITMN-191	Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay	[PMID: 20541424]
Huh-7	EC₅₀	2.4 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA	[PMID: 23672640]
Huh-7	EC₅₀	20 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 3 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis Antiviral activity against Hepatitis C virus genotype 3 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis	[PMID: 23672640]
Huh-7	EC₅₀	20 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 2 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis Antiviral activity against Hepatitis C virus genotype 2 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis	[PMID: 23672640]
Huh-7	IC₅₀	5.7 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay	[PMID: 23672640]

In Vitro

In Huh7.5 cells transfected with chimeric recombinant virus, Danoprevir (ITMN-191) shows antiviral inhibition effects against HCV genotypes 1, 4 and 6 with IC₅₀ of 2-3 nM, which are >100-fold lower than genotypes 2/3/5 (280-750 nM)^[1].
Danoprevir (ITMN-191) inhibits the reference genotype 1 NS3/4A protease half-maximally, but a high dose of Danoprevir (ITMN-191) (10 μM) shows no appreciably inhibition in a panel of 79 proteases, ion channels, transporters, and cell surface receptors. Danoprevir (ITMN-191) remains bound to and inhibits NS3/4A for more than 5 hours after its initial association. Danoprevir (ITMN-191) (45 nM) eliminates a patient-derived HCV genotype 1b replicon from hepatocyte-derived Huh7 cells with an EC₅₀ of 1.8 nM^[2].
In HCV subgenomic replicon cell lines containing the individual mutations, V36M, R109K, and V170A substitutions confer little or no resistance to Danoprevir (ITMN-191), but the R155K substitution confers a high level (62-fold increase) of resistance to Danoprevir^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Danoprevir (ITMN-191) (30 mg/kg, p.o.) administered to rats or monkeys shows that its concentrations in liver 12 hours after dosing exceed the Danoprevir concentration required to eliminate replicon RNA from cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

731.83

Formula

C₃₅H₄₆FN₅O₉S

CAS No.

850876-88-9

Appearance

Solid

Color

White to off-white

SMILES

O=S(NC([C@@]1(NC([C@]2([H])C[C@@H](OC(N3CC4=C(C3)C=CC=C4F)=O)CN2C5=O)=O)C[C@]1(/C=C/CCCCC[C@@H]5NC(OC(C)(C)C)=O)[H])=O)(C6CC6)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (136.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.3664 mL	6.8322 mL	13.6644 mL
5 mM	0.2733 mL	1.3664 mL	2.7329 mL
10 mM	0.1366 mL	0.6832 mL	1.3664 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.69%

Select Batch:

Data Sheet (290 KB) SDS (393 KB)

COA (265 KB) HNMR (238 KB) RP-HPLC (252 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. Imhof I, et al. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).Hepatology. 2011 Apr;53(4):1090-9. [Content Brief]

[2]. Seiwert, Scott D., et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrobial Agents and Chemotherapy (2008), 52(12), 4432-4441.

[3]. Bartels DJ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008 Sep 15;198(6):800-7. [Content Brief]

[4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]

Kinase Assay ^[2]	The assay buffer contains 25 μM NS4A peptide, 50 mM Tris-HCl, pH 7.5, 15% (vol/vol) glycerol, 0.6 mM lauryldimethylamine N-oxide, 10 mM dithiothreitol, and 0.5 μM fluorescein/QXL520-labeled FRET substrate {Ac-DE-Dap(QXL520)-EE-Abu-ψ-[COO]-AS-Cys(5-FAMsp)-NH2}. K2040 enzyme (50 pM) is added to initiate the reaction. Reactions are set up in black 96-well plates, and fluorescence data is collected. Control reactions lacking inhibitors and enzyme are included. Initial rates are calculated from the linear phase of the reaction (up to 1 hour) and are used to obtain IC₅₀. Recovery of activity from preformed Danoprevir-NS3/4A complex is assessed by preincubating 10 nM NS3/4A with a two-fold excess of Danoprevir in 1× assay buffer for 15 min, followed by a rapid 200-fold dilution of the preformed complex into assay buffer containing substrate. A control reaction with the same final conditions without preincubation of NS3/4A and Danoprevir is initiated by the addition of enzyme to an otherwise-complete reaction mixture. Additional control reactions lack either Danoprevir or NS3. The progress of the reactions is followed over 5 hours. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Pharmacokinetic properties are evaluated in rats and monkeys. Sprague-Dawley rats (three per time point) are administered a 30-mg/kg of body weight dose of ITMN-191 by oral gavage (a 6-mg/mL solution in water). Cynomolgus monkeys (two per time point) are administered a 30-mg/kg dose of ITMN-191 by oral gavage (a 3-mg/mL solution in water). For each species, terminal blood samples and the entire perfused liver are collected 1, 4, 8, 12, and 24 h after dose administration. Blood samples are collected in EDTA, processed for plasma by centrifugation at 5°C, and stored at −20°C until analysis is performed. Liver samples are snap-frozen and stored at −70°C until analysis is performed. Blank, standard, and unknown plasma samples and homogenized liver containing an internal standard (ITMN-191 analog) are treated with acidified acetonitrile and centrifuged to remove precipitated proteins. The density of liver tissue is taken into account to allow concentrations in both compartments to be expressed as weight per unit volume. The cleared supernatants are diluted 1:1 into high-performance liquid chromatography grade water and analyzed on a 4000 Q-trap liquid chromatography-tandem mass spectrometer fitted with the Turbo-Ionspray source operating in negative-ion mode. Analytes and internal standards are monitored using multiple-reaction-monitoring scans and calibrated with ABI Analyst software, version 1.4.2. The calibration standards ranges from 0.0169 ng/mL to 37.0 ng/mL and from 7.47 ng/mL to 5,440 ng/mL for the quantification of plasma samples and liver homogenates, respectively. Quadratic fitting with 1/x weighting is utilized where an R2 value of > 0.999 is achieved in both matrices. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Imhof I, et al. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).Hepatology. 2011 Apr;53(4):1090-9. [Content Brief] [2]. Seiwert, Scott D., et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrobial Agents and Chemotherapy (2008), 52(12), 4432-4441. [3]. Bartels DJ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008 Sep 15;198(6):800-7. [Content Brief] [4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.3664 mL	6.8322 mL	13.6644 mL	34.1609 mL
	5 mM	0.2733 mL	1.3664 mL	2.7329 mL	6.8322 mL
	10 mM	0.1366 mL	0.6832 mL	1.3664 mL	3.4161 mL
	15 mM	0.0911 mL	0.4555 mL	0.9110 mL	2.2774 mL
	20 mM	0.0683 mL	0.3416 mL	0.6832 mL	1.7080 mL
	25 mM	0.0547 mL	0.2733 mL	0.5466 mL	1.3664 mL
	30 mM	0.0455 mL	0.2277 mL	0.4555 mL	1.1387 mL
	40 mM	0.0342 mL	0.1708 mL	0.3416 mL	0.8540 mL
	50 mM	0.0273 mL	0.1366 mL	0.2733 mL	0.6832 mL
	60 mM	0.0228 mL	0.1139 mL	0.2277 mL	0.5693 mL
	80 mM	0.0171 mL	0.0854 mL	0.1708 mL	0.4270 mL
	100 mM	0.0137 mL	0.0683 mL	0.1366 mL	0.3416 mL

Danoprevir Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Danoprevir (Synonyms: ITMN-191; R7227; RO5190591; RG7227)

Customer Review

Other Forms of Danoprevir:

17 Publications Citing Use of MCE Danoprevir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Danoprevir Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Danoprevir (Synonyms: ITMN-191; R7227; RO5190591; RG7227)

Customer Review

Other Forms of Danoprevir:

Danoprevir Related Antibodies

17 Publications Citing Use of MCE Danoprevir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Danoprevir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Danoprevir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report